SLN (Silence Therapeutics) Beneish M-Score: 31.31 (As of Jun. 25, 2026)


SLN Silence Therapeutics PLC SLN
44 GF Score
Price $9.16
GF Value $0.21
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Silence Therapeutics Beneish M-Score?

Silence Therapeutics SLN +25.48% 44 Beneish M-Score is 31.31 as of Jun. 25, 2026. GuruFocus rates SLN with a GF Score™ of 44/100 and a GF Value™ of $0.21 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 831 Biotechnology companies, Silence Therapeutics ranks worse than 97.11% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 31.31 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Silence Therapeutics's Beneish M-Score or its related term are showing as below:

SLN' s Beneish M-Score Range Over the Past 10 Years
Min: -4.17   Med: -2.2   Max: 49.22
Current: 31.31

During the past 13 years, the highest Beneish M-Score of Silence Therapeutics was 49.22. The lowest was -4.17. And the median was -2.20.


Silence Therapeutics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Silence Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silence Therapeutics Beneish M-Score Chart

Silence Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.17 -1.74 -2.44 -2.20 49.22

Silence Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.12 -2.09 -2.79 49.22 31.31

SLN vs CRBP, TTRX, AGEN: Beneish M-Score Comparison

For the Biotechnology subindustry, Silence Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silence Therapeutics Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Beneish M-Score falls into.


SLN
44GF Score
Silence Therapeutics PLC SLN
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Silence Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Silence Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 43.5647+0.528 * 0.8463+0.404 * 1.2603+0.892 * 0.0303+0.115 * 0.9591
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 25.6337+4.679 * -0.069899-0.327 * 0.8776
=31.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $22.22 Mil.
Revenue was 0.422 + 0.034 + 0.159 + 0.224 = $0.84 Mil.
Gross Profit was 0.411 + 0.022 + 0.095 + 0.139 = $0.67 Mil.
Total Current Assets was $102.85 Mil.
Total Assets was $115.12 Mil.
Property, Plant and Equipment(Net PPE) was $1.54 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.52 Mil.
Selling, General, & Admin. Expense(SGA) was $21.69 Mil.
Total Current Liabilities was $10.46 Mil.
Long-Term Debt & Capital Lease Obligation was $0.04 Mil.
Net Income was -14.957 + -11.77 + -20.958 + -27.354 = $-75.04 Mil.
Non Operating Income was 0.78 + -2.789 + 5.287 + -4.705 = $-1.43 Mil.
Cash Flow from Operations was -15.603 + -17.287 + -10.891 + -21.784 = $-65.57 Mil.
Total Receivables was $16.84 Mil.
Revenue was 0.142 + 25.305 + 1.498 + 0.756 = $27.70 Mil.
Gross Profit was 0.088 + 23.267 + -2.141 + -2.577 = $18.64 Mil.
Total Current Assets was $169.79 Mil.
Total Assets was $185.30 Mil.
Property, Plant and Equipment(Net PPE) was $1.80 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.58 Mil.
Selling, General, & Admin. Expense(SGA) was $27.93 Mil.
Total Current Liabilities was $19.26 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(22.216 / 0.839) / (16.837 / 27.701)
=26.479142 / 0.607812
=43.5647

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(18.637 / 27.701) / (0.667 / 0.839)
=0.672792 / 0.794994
=0.8463

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (102.852 + 1.538) / 115.123) / (1 - (169.79 + 1.8) / 185.298)
=0.093231 / 0.073978
=1.2603

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.839 / 27.701
=0.0303

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.579 / (0.579 + 1.8)) / (0.523 / (0.523 + 1.538))
=0.24338 / 0.25376
=0.9591

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(21.686 / 0.839) / (27.932 / 27.701)
=25.847437 / 1.008339
=25.6337

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.043 + 10.46) / 115.123) / ((0 + 19.264) / 185.298)
=0.091233 / 0.103962
=0.8776

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-75.039 - -1.427 - -65.565) / 115.123
=-0.069899

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Silence Therapeutics has a M-score of 31.31 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 31.31 mean?
Silence Therapeutics (SLN) has a Beneish M-Score of 31.31 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Silence Therapeutics and its competitors. According to the industry distribution chart, Silence Therapeutics ranks #807 out of 831 companies in the Biotechnology industry, placing it in the top 97.1%.
Is Silence Therapeutics' Beneish M-Score too high?
Silence Therapeutics' current Beneish M-Score is 31.31. Based on the distribution chart, Silence Therapeutics ranks #807 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Silence Therapeutics has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' Beneish M-Score compare to CRBP and TTRX?
According to the Biotechnology industry distribution chart, Silence Therapeutics ranks #807 out of 831 companies for Beneish M-Score. This places Silence Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Silence Therapeutics and its competitors. Silence Therapeutics's current Beneish M-Score is 31.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (SLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.21, compared to a current price of $9.16 — trading 4261.9% above its estimated fair value. The current Beneish M-Score is 31.31. Silence Therapeutics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Silence Therapeutics (SLN), the current Beneish M-Score is 31.31 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Silence Therapeutics (SLN) Overvalued in 2026?

Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued. The current stock price of $9.16 is trading 4261.9% above its estimated GF Value™ of $0.21. GuruFocus considers Silence Therapeutics to be Significantly Overvalued.

Key valuation signals for SLN:

  • Beneish M-Score: 31.31
  • GF Value™: $0.21 vs. price of $9.16 (4261.9% above fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Silence Therapeutics Business Description

Other Exchanges SLNCF:USAXRP2:Germany
Address 12 Hammersmith Grove, London, GBR, W6 7AP
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
44GF Score

Get the complete analysis for SLN

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.16
Price
$0.21
GF Value